Koninklijke Philips Adr Each Rep 1 Ord Eur0.20 (PHG) Stock
Medical device maker powering modern hospital care. Here's the price, business snapshot, and what's worth knowing about Koninklijke Philips Adr Each Rep 1 Ord Eur0.20 in November 2026.
Koninklijke Philips N.V. (PHG) is a Dutch health‑technology company that designs and sells medical devices and related services across diagnostic imaging, patient monitoring, and respiratory care. After refocusing away from consumer appliances, Philips now emphasises hospital equipment, connected care and health informatics — areas driven by ageing populations and digital healthcare adoption. Investors should note a market capitalisation around $27.5 billion and a business mix of product sales, long‑term service contracts and software subscriptions, which can smooth revenues but requires sustained R&D and capital investment. Key considerations include regulatory scrutiny, product quality and lingering legal exposures from past device issues, alongside competition from larger medical‑device peers. Financial metrics to watch are order backlog, service revenue growth, margins and free cash flow. This is general information for educational purposes only; it is not investment advice and investors should assess suitability against their own objectives and risk tolerance.
Why It’s Moving
Philips Shares Surge on Q3 Earnings Beat and Resolution of Respironics Legal Investigations
- Q3 comparable sales grew 3% and equipment order intake rose 8%, with adjusted EBITA margins expanding by 70 basis points to 13%, signaling improved profitability across all business segments.
- The company announced a preliminary agreement in principle with the US DOJ to end criminal and civil investigations linked to Respironics product recalls, removing a significant regulatory overhang for investors.
- CEO Roy Jakobs highlighted broad-based momentum in Diagnosis & Treatment and growth in Personal Health and Connected Care, while reiterating the full-year 2026 outlook despite flat sales in some diagnostic areas.
Philips Shares Surge on Q3 Earnings Beat and Resolution of Respironics Legal Investigations
- Q3 comparable sales grew 3% and equipment order intake rose 8%, with adjusted EBITA margins expanding by 70 basis points to 13%, signaling improved profitability across all business segments.
- The company announced a preliminary agreement in principle with the US DOJ to end criminal and civil investigations linked to Respironics product recalls, removing a significant regulatory overhang for investors.
- CEO Roy Jakobs highlighted broad-based momentum in Diagnosis & Treatment and growth in Personal Health and Connected Care, while reiterating the full-year 2026 outlook despite flat sales in some diagnostic areas.
Sixth Month Growth Performance
When is the next earnings date for KONINKLIJKE PHILIPS NV ADR EACH REP 1 ORD EUR0.20 (PHG)?
The next earnings date for PHG has not been confirmed yet. Based on the company's historical reporting pattern, which typically follows a quarterly cycle with reports occurring approximately three months after the previous release, the upcoming announcement is expected in early November 2026. This report will cover the third quarter of fiscal year 2026. Investors should monitor official communications for the precise scheduling details as they become available.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Philips' stock as its target price is slightly below the current price.
Financial Health
Philips is generating solid revenue, cash flow, and profits, indicating a stable financial position.
Dividend
Philips' average dividend yield of 3.09% makes it a reasonable choice for dividend-seeking investors. If you invested $1000 you would be paid $30.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring revenue mix
Services and software subscriptions can stabilise revenue streams, though growth depends on hospital budgets and successful product roll‑outs.
Global healthcare trends
Ageing populations and digital health uptake support long‑term demand, while emerging‑market expansion offers opportunity amid local competition.
Regulatory and quality focus
Product safety and regulatory compliance are critical; past device issues highlight the potential for reputational and financial impact.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
